Recipient-Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma-An ELTR Study.

IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Christian Tibor Josef Magyar, Noah Free Arteaga, Giacomo Germani, Vincent Hassan Karam, Rene Adam, Renato Romagnoli, Paolo De Simone, Fabien Robin, Daniel Cherqui, Andrea Boscà, Vincenzo Mazzaferro, Yiliam Fundora, Michael Heneghan, Laura Llado, Mickael Lesurtel, Matteo Cescon, Darius Mirza, Andrea Cavelti, Lucienne Christen, Federico Storni, Corina Kim-Fuchs, Anja Lachenmayer, Guido Beldi, Daniel Candinas, Iuliana-Pompilia Radu, Birgit Schwacha-Eipper, Annalisa Berzigotti, Vanessa Banz
{"title":"Recipient-Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma-An ELTR Study.","authors":"Christian Tibor Josef Magyar, Noah Free Arteaga, Giacomo Germani, Vincent Hassan Karam, Rene Adam, Renato Romagnoli, Paolo De Simone, Fabien Robin, Daniel Cherqui, Andrea Boscà, Vincenzo Mazzaferro, Yiliam Fundora, Michael Heneghan, Laura Llado, Mickael Lesurtel, Matteo Cescon, Darius Mirza, Andrea Cavelti, Lucienne Christen, Federico Storni, Corina Kim-Fuchs, Anja Lachenmayer, Guido Beldi, Daniel Candinas, Iuliana-Pompilia Radu, Birgit Schwacha-Eipper, Annalisa Berzigotti, Vanessa Banz","doi":"10.1111/liv.16178","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Liver transplantation (LT) is a curative treatment option. We investigated survival outcomes based on recipient-donor sex constellation (RDSC) following LT.</p><p><strong>Methods: </strong>We performed a European Liver Transplant Registry analysis, including patients from 1988 to December 2022. The cohort was split into four RDSC groups: female donor female recipient (FDFR), female donor male recipient (FDMR), male donor female recipient (MDFR) and male donor male recipient (MDMR). Survival analysis, including death with recurrence, was performed.</p><p><strong>Results: </strong>In 7601 LT for HCC with an overall median follow-up of 22.6 months (5.8, 60.7), death was registered in 25.1% and, as primary cause of death, HCC tumour recurrence in 26.0%. There was no statistically significant difference on crude survival estimates among the different RDSC groups (log-rank p = 0.66) with 10-year overall survival (OS) of 54.5% in FDFR, 54.6% in FDMR, 59.1% in MDFR and 56.9% in MDMR. On multivariable analysis, RDSC showed a significant effect on OS (FDFR as reference): MDFR (aHR 0.72, p = 0.023). No significant difference was found for FDMR (aHR 0.98, p = 0.821) and MDMR (aHR 0.90, p= 0.288). Regarding overall registered causes of death, differences between RDSC groups were found in rejection (p = 0.017) and cardiovascular (p = 0.046) associated deaths.</p><p><strong>Conclusions: </strong>In female recipients undergoing LT for HCC, male donor grafts were associated with a 28% reduction of mortality compared to female donor grafts.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/liv.16178","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Liver transplantation (LT) is a curative treatment option. We investigated survival outcomes based on recipient-donor sex constellation (RDSC) following LT.

Methods: We performed a European Liver Transplant Registry analysis, including patients from 1988 to December 2022. The cohort was split into four RDSC groups: female donor female recipient (FDFR), female donor male recipient (FDMR), male donor female recipient (MDFR) and male donor male recipient (MDMR). Survival analysis, including death with recurrence, was performed.

Results: In 7601 LT for HCC with an overall median follow-up of 22.6 months (5.8, 60.7), death was registered in 25.1% and, as primary cause of death, HCC tumour recurrence in 26.0%. There was no statistically significant difference on crude survival estimates among the different RDSC groups (log-rank p = 0.66) with 10-year overall survival (OS) of 54.5% in FDFR, 54.6% in FDMR, 59.1% in MDFR and 56.9% in MDMR. On multivariable analysis, RDSC showed a significant effect on OS (FDFR as reference): MDFR (aHR 0.72, p = 0.023). No significant difference was found for FDMR (aHR 0.98, p = 0.821) and MDMR (aHR 0.90, p= 0.288). Regarding overall registered causes of death, differences between RDSC groups were found in rejection (p = 0.017) and cardiovascular (p = 0.046) associated deaths.

Conclusions: In female recipients undergoing LT for HCC, male donor grafts were associated with a 28% reduction of mortality compared to female donor grafts.

肝细胞癌肝移植中受体与供体的性别构成--一项 ELTR 研究。
背景与目的:肝细胞癌(HCC)是全球癌症相关死亡的第三大原因。肝移植(LT)是一种可治愈的治疗方法。我们研究了基于受体-供体性别组合(RDSC)的肝移植后生存结果:我们进行了一项欧洲肝移植登记分析,包括1988年至2022年12月的患者。队列分为四个 RDSC 组:女性供体女性受体 (FDFR)、女性供体男性受体 (FDMR)、男性供体女性受体 (MDFR) 和男性供体男性受体 (MDMR)。进行了包括复发死亡在内的生存分析:结果:在 7 601 例因 HCC 而接受 LT 的患者中,总体中位随访时间为 22.6 个月(5.8-60.7 个月),25.1% 的患者死亡,26.0% 的患者死亡的主要原因是 HCC 肿瘤复发。不同 RDSC 组间的粗略生存期估计值无明显统计学差异(log-rank p = 0.66),FDFR 的 10 年总生存期(OS)为 54.5%,FDMR 为 54.6%,MDFR 为 59.1%,MDMR 为 56.9%。多变量分析显示,RDSC对OS有显著影响(以FDFR为参照):MDFR(aHR 0.72,p = 0.023)。FDMR(aHR 0.98,p= 0.821)和MDMR(aHR 0.90,p= 0.288)无明显差异。在登记的总体死因方面,RDSC 组之间在排斥反应(p = 0.017)和心血管相关死亡(p = 0.046)方面存在差异:结论:在接受LT治疗HCC的女性受者中,男性供体移植物与女性供体移植物相比,死亡率降低了28%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Liver International
Liver International 医学-胃肠肝病学
CiteScore
13.90
自引率
4.50%
发文量
348
审稿时长
2 months
期刊介绍: Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信